Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.58 |
| ▸ | F3 | P13726 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | USP7 | Q93009 | 1/20 | 0.58 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.58 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6816946 | 1.00 | ALOX5 (0.63) | ALOX5PTPN1F3USP2LMNA | |
| SCHEMBL12509508 | 1.00 | ALOX5 (0.63) | ALOX5PTPN1F3USP2LMNA | |
| SCHEMBL13984298 | 0.92 | ALOX5 (0.62) | ALOX5PTPN1F3USP2LMNA | |
| SCHEMBL20130493 | 0.91 | ALOX5 (0.61) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL12509509 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL12422241 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL398310 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL8339201 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL2895626 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL6235008 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-10 | — | — | US | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | disclosed |
| US-8557844-B2 | Substrate reduction therapy | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | UGCG, SMPD1, SMPD4 | ALOX5 1633/4885PTPN1 2937/4885F3 4769/4885 |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | ALOX5 1666/4885PTPN1 4022/4885F3 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.